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Background: The purpose of the Occluded Artery Trial (OAT) Biomarker substudy was to evaluate the impact of
infarct related artery (IRA) revascularization on serial levels of N-terminal prohormone of brain natriuretic peptide
(NT-proBNP) and dynamics of other biomarkers related to left ventricular remodeling, fibrosis and angiogenesis.
Methods: Patients were eligible for OAT-Biomarker based on the main OAT criteria. Of 70 patients (age 60.8 ± 8.8,
25% women) enrolled in the substudy, 37 were randomized to percutaneous coronary intervention (PCI) and 33 to
optimal medical therapy alone. Baseline serum samples were obtained prior to OAT randomization with follow up
samples taken at one year. The primary outcome was percent change of NT-proBNP from baseline to 1 year. The
secondary outcomes were respective changes of matrix metalloproteinases (MMP) 2 and 9, tissue inhibitor of matrix
metalloproteinase 2 (TIMP-2), Vascular Endothelial Growth Factor (VEGF), and Galectin-3.
Results: Paired (baseline and one-year) serum samples were obtained in 62 subjects. Baseline median NT-proBNP
level was 944.8 (455.3, 1533) ng/L and decreased by 69% during follow-up (p < 0.0001). Baseline MMP-2 and TIMP-2
levels increased significantly from baseline to follow-up (p = 0.034, and p = 0.027 respectively), while MMP-9 level
decreased from baseline (p = 0.038). Levels of VEGF and Galectin-3 remained stable at one year (p = NS for both).
No impact of IRA revascularization on any biomarker dynamics were noted.
Conclusions: There were significant changes in measured biomarkers related to LV remodeling, stress, and fibrosis
following MI between 0 and 12 month. Establishing infarct vessel patency utilizing stenting 24 hours-28 days post
MI did not however influence the biomarkers’ release.
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Myocardial infarction (MI) initiates healing and repair
responses, which include scar formation, angiogenesis
and remodeling. Preliminary data suggested that late
(beyond 24 hours) opening of occluded culprit infarct ar-
tery might have beneficial impact upon these processes,
with subsequent clinical advantages [1]. The Occluded Ar-
tery Trial (OAT) was a randomized trial testing the clinical
effect of mechanical reperfusion versus optimal medical
therapy alone (MED) for totally occluded arteries in stable
patients 3–28 calendar days following MI. The main trial
was powered to evaluate clinical outcomes, and failed
to show any additional benefit of the interventional
treatment over optimal medical therapy [2]. The lack
of observed clinical benefit with percutaneous coronary
intervention (PCI) was also independent of the presence
and degree of viability in the infarct zone [3]. Changing
plasma levels of relevant biomarkers may reflect the
dynamics of these processes more sensitively, and their
assessment may provide additional pathophysiological
insight into the main study clinical findings.
The primary purpose of the OAT Biomarker substudy
was to evaluate the impact of mechanical revascularization
on paired levels of N-terminal prohormone of brain natri-
uretic peptide (NT-proBNP) obtained at baseline and at
1 year of follow up; and secondly to assess the impact of
the randomized treatment on dynamics of biomarkers re-
lated to post-infarction left ventricular remodeling, fibrosis
and angiogenesis, including matrix metalloproteinases
(MMP) 2 and 9 and tissue inhibitor of matrix metallopro-
teinase 2 (TIMP-2), Vascular Endothelial Growth Factor
(VEGF), and galectin-3.
Methods
Study setting & population
The patients were eligible for OAT-Biomarker ancillary
study when they consented for the parent trial OAT (Clini-
calTrials.gov Identifier: NCT00004562). Due to lack of
funding the study was performed in only 10 sites in Poland,
two in Canada and a solitary site in the United States. The
substudy was approved by Institutional Review Board at
each participating center (Terenowa Komisja Bioetyczna
Instytutu Kardiologii; University Health Network Research
Ethics Board; Research Ethics Board, St. Michael’s Hospital;
Ethics Committee, Truman Medical Center) and patients
provided separate written informed consent for the OAT-
Biomarker ancillary study. During follow-up repeated blood
sampling 1 year after randomization was performed. For
ninety percent (62/70) of the patients paired (baseline plus
on-year) blood samples were available.
Laboratory methods and study outcomes
Baseline samples were obtained prior to OAT randomization
and repeated after one year. Blood samples were collectedin tubes without anticoagulant. The samples were then
centrifuged, and serum was stored frozen in aliquots
at -20°C to -80°C at the enrolling site until shipped to the
biomarker core laboratory at the Institute of Cardiology,
where they were maintained at -80°C. Serum NT-proBNP
(sandwich immunoassay) for this batched analysis were
determined using an Elecsys 2010 (Roche Diagnostics
GmbH, Mannheim, Germany). The analytic range of NT-
proBNP assay extends from 5 to 35000 ng/L. The total co-
efficient of variation (CV) was 2.1% at a level of 181 ng/L
and 1.8% at a level of 572 ng/L. Concentrations of matrix
metalloproteinases, tissue inhibitor of metalloproteinase-2
and VEGF were assayed using quantitative sandwich en-
zyme immunoassay technique. The following Quantikine
(R&D Systems, Inc., Minneapolis, MN, USA) tests were
used: human/mouse MMP-2, total (sensitivity =0.16 ng/mL,
intra- and inter-assay precision; CV = 5.7 and 8.2%), hu-
man MMP-9, total, (sensitivity = 0.156 ng/mL, intra- and
inter-assay precision; CV = 2.9 and 7.9%), human TIMP-2
(sensitivity = 0.011 ng/mL, intra- and inter-assay precision;
CV = 4.4 and 7.3%), human VEGF (sensitivity =9.0 pg/mL,
intra- and inter-assay precision; CV = 4.5 and 7.0%).
Concentration of galectin was estimated using human
galectin-3 ELISA kit (Bender MedSystems GmbH,
Vienna, Austria) (sensitivity = 0.12 ng/mL, intra- and
inter-assay precision; CV = 6.4 and 11.4%).
The primary endpoint for this biomarker analysis was
NT-proBNP percent change from baseline to 1 year.
The dynamics of the other biomarkers comprised the
secondary outcomes of the study. The primary clinical
endpoint of OAT was a composite of death from any
cause, reinfarction, or NYHA class IV heart failure with
hospitalization or admission in a short-stay unit with
follow up extending out to 7 years. The study clinical
endpoints were adjudicated by an independent commit-
tee. The definition of reinfarction has been provided
previously [2].
Statistical analysis
Data management and statistical analyses were performed
by the OAT data coordinating center. Baseline biomarkers
were assessed as medians (interquartile range), clinical
characteristics were assessed as frequencies/proportions
or mean ± standard deviation (SD) and compared to the
remaining main OAT patients, as well as by treatment
groups (PCI vs. MED). The nonparametric median
Wilcoxon test, t-test or chi square tests were used for
comparisons as appropriate. The biomarker’s levels were
presented as medians (inter-quartile range), and compared
by means of Wilcoxon Signed Rank test. Two-sided two-
group t-tests at alpha = 0.05 were done for comparisons of
biomarkers changes from baseline to 1-year.
To examine the impact of the study treatment on bio-
marker dynamics, change in biomarkers’ levels between
Table 1 Baseline characteristics
OAT-Biomarker (N = 70) Remaining OAT (N = 2131)
n % (mean ± sd) N % (mean ± sd) p-value
Age (years) 70 (60.8 ± 8.8) 2131 (58.5 ± 11) 0.097
Women 17 24.3 467 21.9 0.637
Race White 70 100 1693 79.4 <.001
Clinical history
Angina 15 21.4 480 22.5 0.829
Myocardial Infarction 3 4.3 244 11.5 0.080
Percutaneous intervention 4 5.7 101 4.7 0.574
Congestive heart failure 1 1.4 51 2.4 1.000
Hypertension 36 51.4 1035 48.6 0.638
Diabetes 10 14.3 444 20.8 0.183
Insulin use 6 8.6 118 5.5 0.279
Hypercholesterolemia 31 44.3 1111 52.2 0.195
Stroke 4 5.7 59 2.8 0.138
Cerebrovascular disease 5 7.1 77 3.6 0.125
Peripheral vascular disease 1 1.4 82 3.9 0.519
Current Smoker 25 35.7 834 39.1 0.564
Family history CAD 29 41.4 854 40.1 0.820
Days from MI to randomization - median {IQR} 70 21{16–26} 2131 8{5–16} <.001
Index myocardial infarction
Received thrombolytics 1 1.4 423 19.9 <.001
STE / Q wave / R loss 58 82.9 1849 86.8 0.344
Killip Class II-IV 11 15.7 406 19.1 0.473
Ejection Fraction 70 (46.3 ± 9.7) 2115 (47.8 ± 11.1) 0.275
Rales 1 1.4 136 6.4 0.125
Clinical measures
Estimated GFR <60 ml/min/1.73 m2 8 11.4 305 14.6 0.453
Glucose > =126 mg/dl 8 11.6 556 28.8 0.002
BMI (kg/m2) 69 (26.7 ± 3.6) 2118 (28.6 ± 5.1) 0.003
Heart rate (bpm) 70 (69.3 ± 9.8) 2128 (71.9 ± 12) 0.076
Systolic blood pressure (mmHg) 70 (120.4 ± 11.9) 2129 (120.8 ± 18.1) 0.831
Angiography
Infarct-related artery (IRA) –LAD 19 27.1 774 36.3 . 0.267
Infarct-related artery (IRA) –Lcx 11 15.7 324 15.2
Infarct-related artery (IRA) –RCA 40 57.1 1033 48.5
Multivessel Disease 21 30.4 358 16.9 0.004
Collaterals 64 92.8 1858 88.3 0.256
Medications
Aspirin 68 97.1 2037 95.6 0.767
Thienopyridine 42 60 1287 60.4 0.947
Warfarin 3 4.3 212 9.9 0.150
Beta blocker 65 92.9 1867 87.6 0.187
Calcium blocker 2 2.9 127 6 0.434
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Table 1 Baseline characteristics (Continued)
Lipid lowering agent 68 97.1 1720 80.7 <.001
Spironolactone 9 12.9 115 5.4 0.008
ACE-Inhibitor or ARB 62 88.6 1709 80.2 0.082
ACE-angiotensin converting enzyme, ARB-angiotensin receptor blocker, BMI-body mass index, BP, blood pressure, CAD-coronary artery disease, GFR-glomerular
filtration rate, IQR-interquartile ranges, IRA-infarct related artery, LAD-left anterior descending artery, LCX-left circumflex coronary artery, RCA-right coronary artery,
STE-ST elevation.
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ment (PCI versus MED). The independent correlates of
NT-proBNP and other biomarkers dynamics (change from
baseline to one year levels) were assessed by means of re-
gression analyses. The univariate models were run first to
identify any predictor significant at 0.10 level. Then a
backward selection was run on the multivariate model to
determine the final predictors that were still significant at
0.05 level. The treatment group was forced into the multi-
variable models. For the biomarkers dynamics (baseline
versus follow-up), biomarkers dynamics between PCI
versus MED subgroups, and for regression models with
NT-proBNP dynamics as the dependent variable, signifi-
cance level was set at p < 0.05. For other analyses signifi-
cance level was set at p < 0.01. All analyses are performed
on an intention-to-treat basis.
With a targeted sample size of 200 patients and a pre-
dicted standard deviation of 50% for change in biomarker
levels from baseline to 1 year, there would be 80% power
to detect a 22% difference in NT-proBNP change between
the treatment groups in the presence of a 15% drop-out
rate. With the observed SD of 76% and sample size of 62
(paired samples), there was 80% power to detect a
difference of 56% for the primary outcome of change in
NT-proBNP levels from baseline to 1 year.
Results
Baseline characteristics
Patient characteristics at study baseline and comparison
to the main OAT cohort are illustrated in Table 1. The
mean age of enrolled patients was 60.8 ± 8.8 years, all
patients were white (p < 0.001 when compared to the
main OAT), and 17 (25%) were women. Patients en-
rolled in the biomarker substudy had a longer time from
MI to randomization, less thrombolytic therapy for the
index event, lower prevalence of multivessel disease,
and higher use of lipid lowering medications and spir-
onolactone (Table 1). Overall, thirty seven biomarker
study subjects were randomized to PCI while 33 were in
the control arm. Patients randomized to medical therapy
alone had less diabetes and received less thienopyridines,
when compared to the PCI group (Table 2).
Biomarkers
Baseline levels of NT-proBNP were 944.8 (455.3, 1533) ng/L
and decreased by 69% to 266.8 (138.2, 584.9) ng/L duringfollow-up (p < 0.0001). During this period MMP-2 [185.7
(172.3, 219.4) ng/mL versus 216.9 (176, 249.9) ng/mL, p =
0.034] and TIMP-2 levels [64.5 (58.6, 71) ng/mL versus 69.1
(62.6, 74.4) ng/mL, p = 0.027] increased significantly from
baseline to follow-up. In contrast, MMP-9 levels decreased
from 101.6 (53.5, 170.2) ng/mL to 80.2 (43.7, 150.2) ng/mL
(p = 0.038) while levels of VEGF [39.9 (21.7, 83.7) pg/mL
vs. 48.3 (19.6, 82.5) p = 0.291], and Galectin [12.8 (9.4,
15.2) ng/mL vs. 12.8 (10.1, 15.4) ng/mL, p = 0.561] remained
stable (Figure 1).
Impact of PCI on biomarker levels
The percent change from baseline to one year levels of
NT-proBNP was significant within both PCI and MED
subgroups. There was a trend toward increased MMP-2
in medically treated patients only, and MMP-9 tended to
decrease in PCI but not in medically treated patients
(Figure 2). Follow-up levels of the examined biomarkers
and their changes over time did not differ significantly
for the PCI versus MED subgroups (Figure 2).
Predictors of the biomarkers’ dynamics
The univariate and multivariable predictors of biomarker
changes over time are provided in Table 3. Percent
change of NT pro-BNP was predicted independently by
its baseline level and family history of coronary disease.
For the other biomarkers, their dynamics were inde-
pendently predicted by their respective baseline values.
Additionally, changes in VEGF were correlated to previ-
ous thrombolytic therapy; while changes in TIMP-2
were related to history of renal insufficiency, baseline
heart rate and BMI. Galectin changes were related to
BMI (Table 3).
Discussion
This is a small, serial measurement of biomarkers sub-
study performed under the auspices of a large phase 3
rigorously performed randomized clinical trial. Despite
its small size, the unique patient characteristics and the
protocol assigned PCI in the background of a late totally
occluded infarct related artery makes these observations
notable. The differences in baseline characteristics from
the parent trial likely reflect geographic characteristics
arising from randomization in Poland which accounted
for all of the paired samples considered for analysis.
Prior analyses of the main trial demonstrated similar
Table 2 Baseline biomarker and patient characteristics by treatment assignment
PCI (N = 37) MED (N = 33)
n % (mean ± sd) median{interquartile
range}*




Baseline NT-proBNP(ng/L){IQR} 37 846.1{402.4,1488} 33 1100{474.6,1726} 0.306
Baseline VEGF(pg/mL){IQR} 31 42.5{23.6,207.2} 27 37.5{17.4,70.2} 0.293
Baseline MMP-2(ng/mL){IQR} 33 185.7{172.3,216.9} 28 185.3{172.1,239.7} 0.879
Baseline MMP-9(ng/mL){IQR} 33 90{56,185} 28 102.3{44.2,163.2} 0.506
Baseline TIMP-2(ng/mL){IQR} 33 64.5{57.6,74.1} 28 64.3{59.2,70} 0.789
Baseline GALECTIN(ng/L){IQR} 33 12.8{9.8,15.5} 28 13{9.2,14.9} 0.806
Age (years) 37 (62.5 ± 9.1) 33 (58.8 ± 8.1) 0.086
Female 11 29.7 6 18.2 0.261
Race White 37 100 33 100 .
Clinical History
Angina 8 21.6 7 21.2 0.967
Myocardial infarction 1 2.7 2 6.1 0.599
Percutaneous coronary intervention 3 8.1 1 3 0.616
Congestive heart failure 0 0 1 3 0.471
Hypertension 21 56.8 15 45.5 0.345
Diabetes 2 5.4 8 24.2 0.038
Insulin use 1 2.7 5 15.2 0.093
Hypercholesterolemia 15 40.5 16 48.5 0.504
Stroke 2 5.4 2 6.1 1.000
Cerebrovascular disease 2 5.4 3 9.1 0.661
Peripheral vascular disease 1 2.7 0 0 1.000
Current Smoker 13 35.1 12 36.4 0.915
Family history CAD 12 32.4 17 51.5 0.106
Days from MI to randomization - median
{IQR}
37 22{17–26} 33 20{14–25} 0.135
Index myocardial infarction
Received thrombolytics 1 2.7 0 0 1.000
STE / Q wave / R loss 30 81.1 28 84.8 0.676
Killip Class II-IV 7 18.9 4 12.1 0.522
Ejection fraction 37 (46.8 ± 9) 33 (45.7 ± 10.5) 0.652
Rales 0 0 1 3.1 0.464
Clinical measures
Estimated GFR <60 ml/min/1.73 m2 5 13.5 3 9.1 0.714
Glucose > =126 mg/dl 2 5.6 6 18.2 0.140
BMI (kg/m2) 37 (26.4 ± 2.8) 32 (27.2 ± 4.3) 0.365
Heart rate (bpm) 37 (68.9 ± 9.4) 33 (69.7 ± 10.3) 0.733
Systolic blood pressure (mmHg) 37 (119.5 ± 11.4) 33 (121.4 ± 12.5) 0.507
Angiography
Infarct-related artery (IRA) LAD 13 35.1 6 18.2 0.240
Infarct-related artery (IRA) Lcx 6 16.2 5 15.2
Infarct-related artery (IRA) RCA 18 48.6 22 66.7
Kruk et al. BMC Cardiovascular Disorders 2013, 13:91 Page 5 of 10
http://www.biomedcentral.com/1471-2261/13/91
Table 2 Baseline biomarker and patient characteristics by treatment assignment (Continued)
Angiography - multivessel disease 9 24.3 12 37.5 0.236
Collaterals 36 97.3 28 87.5 0.175
Medications
Aspirin 36 97.3 32 97 1.000
Thienopyridine 34 91.9 8 24.2 <.001
Warfarin 0 0 3 9.1 0.100
Beta blocker 32 86.5 33 100 0.056
Ca blocker 1 2.7 1 3 1.000
Lipid lowering agent 35 94.6 33 100 0.494
Spironolactone 6 16.2 3 9.1 0.485
ACE-Inhibitor or ARB 32 86.5 30 90.9 0.714
*median(interquartile range) for biomarkers, ACE-angiotensin converting enzyme, ARB-angiotensin receptor blocker, BMI-body mass index, BP = blood pressure,
CAD-coronary artery disease, GFR-glomerular filtration rate, IQR-interquartile ranges, IRA-infarct related artery, LAD-left anterior descending artery, LCX-left
circumflex coronary artery, MED – medical therapy alone, PCI- percutaneous coronary intervention, RCA-right coronary artery, STE-ST elevation.
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that the plasma levels of biomarkers related to LV func-
tion and remodeling, including NT-proBNP, MMP-2,
TIMP-2 and MMP-9, significantly evolved from baseline
to one year following index MI. However, the change in
biomarkers levels were not significantly modified by
mechanical opening of the occluded infarct related ar-
tery (IRA) performed 3 to 28 days post MI.
NT-proBNP is an established biomarker used for diag-
nosis, prognosis and in selected cases management of pa-
tients with heart failure or acute coronary syndromes. It isFigure 1 Baseline to one-year, median percent change of the bioma
natriuretic peptide; MMP-matrix metalloproteinase; TIMP - tissue inh
Growth Factor.synthesized in the ventricular myocardium in response to
increased wall tension, myocardial stretch or ischemia
[4-6]. The kinetics of NT-proBNP in the early post infarc-
tion period have been previously reported. An early rise is
seen beginning immediately after the index infarct that
has a second peak at about 24 hours. Subsequently NT-
proBNP levels plateau at approximately 35 days. Plasma
levels of NTpro-BNP chave been shown to correlate with
cardiac function following myocardial infarction [7], as
well as with mortality in heart failure or acute coronary
syndromes. Serial changes of NT-proBNP parallelrker levels; NT-proBNP- N-terminal prohormone of brain
ibitor of matrix metalloproteinase; VEGF-Vascular Endothelial
Figure 2 Baseline to one-year changes of the examined biomarkers’ levels by the study treatment (recanalization of infarct related
artery (PCI) versus medical therapy alone (MED)). (A) - NT-proBNP- N-terminal prohormone of brain natriuretic peptide; (B) - VEGF-Vascular
Endothelial Growth Factor; (C) - MMP-2-matrix metalloproteinase-2; (D) - MMP-9-matrix metalloproteinase-9; (E) - TIMP-2 - tissue inhibitor of
matrix metalloproteinase-2; (F) - Galectin.
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study of FRISC-II trial, higher baseline levels of NT-
proBNP were shown to identify the subgroup of
NSTE-ACS patients benefitting from interventional
treatment [10]. The decline of NT-proBNP observed in
OAT-Biomarker likely reflects gradual improvement of
cardiac function (ejection fraction) directly observed in
OAT-NUC and TOSCA 2 ancillary studies [3,11]. We
observed a lack of impact of the IRA recanalization on
biomarker changes over one year. These findings are
consistent with the lack of clinical benefit observed
with PCI in the parent trial. Importantly, majority
(89%) of the study patients received ACE inhibitors or
angiotensin receptor-1 blockers, therefore the hypothetical
impact of the study PCI was tested on top of optimal
medical therapy, which itself had been shown to lower
natriuretic peptide levels in patients with LV dysfunc-
tion [12].
Matrix metalloproteinases (MMP) and their tissue in-
hibitors (TIMPs) are enzymes involved in the extracellu-
lar matrix turnover and cardiac remodeling following
infarction. Their release and roles following MI are time
dependent [13,14]. Prior studies reported a cause-effect
relation between MMP-2,-9 and adverse LV myocardial
remodeling after MI [15,16]. MMP-2 and −9 levels were
shown to correlate with echo measures of LV remodel-
ing and non scarred myocardial mass on CMR [17-19].Existing evidence supports clinical testing of MMP in-
hibitors for prevention of postinfarction remodeling in
humans [13,20].
In our cohort the values of MMP-2 significantly in-
creased, while MMP-9 decreased from baseline. Similar
shifts in these biomarker levels during long-term follow-
up were previously observed in patients after MI
[17,18,21,22]. In our study, PCI tended to decrease
MMP-9 levels more significantly than medical therapy
alone (respectively 38% vs. 5%). Regarding MMP-2, PCI
had no visible effect on its dynamics.
TIMP-2 may either inhibit or stimulate activation of
MMP-2 [23,24]. Its deficiency has been shown to acceler-
ate post infarction LV remodeling in an animal model
[25]. Plasma levels of TIMP-2 have been shown to in-
crease in late stages of MI, as we observed in our cohort
[17]. In the current study, TIMP-2 rise was positively
correlated with history of renal insufficiency and heart rate
and negatively with body mass index. However, PCI of
IRA did not significantly impact alterations in these
marker dynamics.
VEGF is implicated in neovascularization of ischemic
tissue and wound healing, and its levels were previously
shown to be correlated with peak creatine kinase levels
in patients with MI. VEGF elevation has also been
shown to be associated with clinical myocardial ischemia
and adverse outcomes following ACS [26,27]. The only
Table 3 Uni- and multivariable predictors of the biomarkers dynamics (change from baseline to one-year)
Univariable model Multivariable model
Estimate ProbChiSq Estimate ProbChiSq
NT-proBNP Baseline NT-proBNP −0.699 <.001 −0.695 <.001
PCI versus med −6.939 0.979 −253.604 0.162
Famliy history of CAD −511.007 0.052 −448.534 0.015
New Q waves −531.444 0.067 - -
VEGF Baseline VEGF −0.750 <.001 −0.727 <.001
PCI versus med −42.952 0.109 −5.514 0.694
History of cerebrovascular disease −108.966 0.065 - -
Current smoker −53.395 0.049 - -
Thrombolytic therapy 220.645 0.026 171.550 <0.001
MMP-2 Baseline MMP-2 −0.982 <.001 −0.979 <.001
PCI versus med. −51.316 0.351 −11.677 0.384
systolic blood pressure (10 mmHg) 40.239 0.079 - -
diastolic blood pressure (10 mmHg) 62.034 0.053 - -
MMP-9 Baseline MMP-9 −0.751 <.001 −0.742 <.001
PCI versus med. −24.601 0.436 0.526 0.981
MI history 122.755 0.081 104.471 0.032
History of cerebrovascular disease −185.871 0.006 - -
Current smoker −58.054 0.068 - -
TIMP-2 Baseline TIMP-2 −0.919 <.001 −0.885 <.001
PCI versus med. 0.412 0.914 −2.558 0.255
Male versus Female 8.349 0.049 - -
History of Renal Insufficiency 17.714 0.085 22.685 0.003
Family history of CAD 6.314 0.099 - -
Current smoker −7.321 0.056 −5.025 0.029
Heart rate (10 beats/minute) 3.213 0.099 3.566 0.002
BMI (10 kg/m2) −9.403 0.087 −11.541 <0.001
GALECTIN Baseline GALECTIN −0.82 <.001 −0.77 <.001
PCI versus med. −0.734 0.674 0.037 0.975
Angina history −3.418 0.087 - -
PCI history 6.348 0.059 - -
Thrombolytic therapy −13.353 0.040 −10.305 0.023
BMI (10 kg/m2) 8.281 <0.001 7.326 <.001
Ejection fraction (10%) −1.983 0.018 - -
NT-proBNP- N-terminal prohormone of brain natriuretic peptide, matrix metalloproteinase-MMP, tissue inhibitor of matrix metalloproteinases- TIMP, Vascular
Endothelial Growth Factor -VEGF.
BMI-body mass index, CAD-coronary artery disease, MED-medical therapy, MMP-matrix metalloproteinase; NT-proBNP- N-terminal prohormone of brain natriuretic
peptide; PCI-percutaneous coronary intervention; TIMP - tissue inhibitor of matrix metalloproteinase; VEGF-Vascular Endothelial Growth Factor.
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study was thrombolytic therapy for the index event. We
did not find any association between the study treatment
and baseline to one-year change of VEGF levels.
Experimental observations suggest that galectin-3 may
be regarded not only as a biomarker but also as an active
mediator of fibrosis causing progression of heart failure
[28,29]. In the clinical setting galectin-3 levels have beenshown to correlate with clinical outcomes in patients
with heart failure, providing incremental prognostic
value to NT-proBNP [30]. In our study no significant
difference was found between median baseline and follow
up values of galectin, nor between PCI and medically
treated patients. However, multivariable analysis identified
thrombolytic therapy and BMI as independent correlates
of the biomarker dynamics over one-year.
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The study cohort represents a small series of patients
enrolled in the main OAT study. The power to detect
small differences in the biomarker dynamics between
the PCI and MED groups was limited due to the insuffi-
cient recruitment relative to initial projections. It is also
conceivable that the differences between the study
groups would differ had the patients been followed for a
longer period of time. Only paired samples at baseline
and 1 year of follow up were available. As a result the
time course of changes during this window could not be
elicited.
Conclusions
The Biomarker ancillary study to OAT suggests that
there are significant dynamic changes (from baseline to
one year) in biomarkers related to LV remodeling, stress,
and fibrosis following MI, however, their dynamics are
not significantly modified by opening of occluded IRA
3 days-28 days post MI. Consistent with the findings of
the parent trial and the nuclear substudy, our findings
appear to also suggest that late IRA recanalization does
not significantly impact mechanisms underlying LV heal-
ing/remodeling processes following MI in patients on
optimal medical therapy.
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